ClinicalTrials.gg
CompletedNCT00780403Updated Feb 9, 2022Results posted

Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)

A Phase 4 interventional study of Desloratadine and Zyrtec® (cetirizine) in Allergies, sponsored by Organon and Co. Completed. Open to participants aged 6 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Study summary

The primary objective of this study was to determine whether children ages 6-11 years prefer desloratadine RediTabs (2.5 mg) or a marketed competitor (Zyrtec® 5 mg Chewable Tablets). The secondary objectives of this study were to compare acceptance of the two attributes, taste and feeling in the mouth, of desloratadine 2.5 mg RediTabs and Zyrtec® 5 mg Chewable Tablets

02

Conditions studied

  • Allergies

Browse trials for

03

In context

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 150 are open to participants now.

This study's enrollment of 220 is above the median of 73 across 691 interventional studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject and the parent/guardian of the subject, was to have demonstrated their willingness to participate in the study and comply with its procedures by signing a written
  • 6-11 years old, either sex, either race
  • If female, subject to be premenarcheal
  • Willing to avoid eating, drinking, gum chewing, and teeth brushing for one hour prior to enrollment.
  • Free of any disease that would interfere with study evaluations, including allergic rhinitis and respiratory infections.
  • Able to adhere to the dosing and visit schedules

Exclusion criteria

Exclusion Criteria:

  • If female, subject who was pregnant, intended to become pregnant during the study or nursing.
  • Subject had used any product within 30 days prior to enrollment.
  • Subject had any of the following clinical conditions: history of any significant medical conditions (based on reporting by parent or guardian): e.g., diabetes, heart disease, liver disease, kidney disease, breathing problems, cough with excessive phlegm, or persistent or chronic cough.
  • Subject had a current medical condition that, in the opinion of the Investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, allergic rhinitis, etc.).
  • Subject was participating in any other clinical study(ies).
  • Subject was part of the staff or a family member of the staff personnel directly involved with this study.
  • Subject was allergic to or has sensitivity to the study drug or its .
  • Subject had a history of allergic reaction to prescription and/or over the counter (OTC) medications and/or food products.
  • Subject had used any antihistamines within 24 hours prior to tasting as outlined in Section 9.4.7.
  • Subject used sedatives, tranquilizers, or monoamine oxidase inhibitor drugs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • Active comparator
    RediTab/Zyrtec

    Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.

    Drug: Desloratadine · Drug: Zyrtec® (cetirizine)

  • Active comparator
    Zyrtec/RediTab

    Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.

    Drug: Desloratadine · Drug: Zyrtec® (cetirizine)

Interventions

  • desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day

    Also known as: SCH 034117

  • Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.

    A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject "now that you have tasted the two tablets, show us which tablet you like more" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.

    Time frame: Following the second dose (8-10 minutes after the first dose)

07

Results

Posted Jul 30, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneRediTab/ZyrtecZyrtec/RediTab
Started109111
Completed109111
Not completed00
Interval Between Doses (8-10 Minutes)
Participant flow — Interval Between Doses (8-10 Minutes)
MilestoneRediTab/ZyrtecZyrtec/RediTab
Started109111
Completed109111
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneRediTab/ZyrtecZyrtec/RediTab
Started109111
Completed109111
Not completed00

Outcome measures

PrimaryNumber of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.

A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject "now that you have tasted the two tablets, show us which tablet you like more" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.

Time frame:
Following the second dose (8-10 minutes after the first dose)
Reported as:
Number · participants
Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.
participantsRediTabZyrtecNo Preference
Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.1493338
Statistical analysis
  • RediTab vs Zyrtec · Mainland-Gart Test · p = <0.0001 (Statistical tests were performed at the significance level of 5%, without multiplicity adjustment.)The p-value was derived from Mainland-Gart Test applied to a 2 (treatment sequence) by 2 (preferred period) contingency table.

Adverse events

Collected over 1 day. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RediTab/Zyrtec—0/109 (0%)0/109 (0%)
Zyrtec/RediTab—0/111 (0%)0/111 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Total Population
Mean8.9 ± 1.65
Sex: Female, Male
Sex: Female, Male(Participants)Total Population
Female109
Male111
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2008
First posted
Oct 27, 2008
Start
Aug 2005
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Results first posted
Jul 30, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00780403
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Oct 27, 2008
Start date
Aug 2005
Primary completion
Oct 2005
Completion
Oct 2005
Results posted
Jul 30, 2010
Last update
Feb 9, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desloratadine · Cetirizine

Start the discussion